Selective immunoglobulin A deficiency (IgAD) is the most common primary immunodeficiency in Europeans. Our genome-wide association study (GWAS) meta-analysis of 1,635 patients with IgAD and 4,852 controls identified four new significant (P < 5 × 10 −8 ) loci and association with a rare IFIH1 variant (p.Ile923Val). Peak new variants (PVT1, P = 4.3 × 10 −11 ; ATG13-AMBRA1, P = 6.7 × 10 −10 ; AHI1, P = 8.4 × 10 −10 ; CLEC16A, P = 1.4 × 10 −9 ) overlapped with autoimmune markers (3/4) and correlated with 21 putative regulatory variants, including expression quantitative trait loci (eQTLs) for AHI1 and DEXI and DNase hypersensitivity sites in FOXP3 + regulatory T cells. Pathway analysis of the meta-analysis results showed striking association with the KEGG pathway for IgA production (pathway P < 0.0001), with 22 of the 30 annotated pathway genes containing at least one variant with P ≤ 0.05 in the IgAD meta-analysis. These data suggest that a complex network of genetic effects, including genes known to influence the biology of IgA production, contributes to IgAD.
IgAD is the most common primary immunodeficiency and is defined by serum IgA levels <0.07 g/l (ref. 1) . Its prevalence in Europeans is 1:600 (ref. 1) . Secretory IgA (sIgA) is important for mucosal immunity and gut commensalism 2, 3 , and clinical features of IgAD include recurrent mucosal infections. In IgAD, B cells fail to terminally differentiate into IgA + plasma cells; however, IL-21 can restore B cell IgA production in vitro 4, 5 . IgAD is strongly associated with the human leukocyte antigen (HLA) locus 6 and aggregates in families with autoimmunity 7 . The prevalence of celiac disease is 35 times higher in patients with IgAD, whereas the prevalence of systemic lupus erythematosus (SLE) and type 1 diabetes (T1D) is 10 times higher 8 .
Ferreira et al. 6 previously imputed HLA-B, HLA-DRB1 and HLA-DQB1 in a study of IgAD cases and controls (>2,700 individuals) 9 . The primary signal mapped to HLA-DQB1*02 (odds ratio (OR) = 2.8, P = 7.7 × 10 −57 ), because of combined independent effects of the HLA-B*08:01-HLA-DRB1*03:01-HLA-DQB1*02 and HLA-DRB1*07:01-HLA-DQB1*02 haplotypes 9 . There was a secondary signal at HLA-DRB1*01:02 (OR = 4.28, P = 5.86 × 10 −17 ) and a protective effect for HLA-DRB1*15:01 (OR = 0.13, P = 2.24 × 10 −35 ) 9 . HLA-DQB1*02:01 is protective for IgA nephropathy (OR = 0.71, P = 2.61 × 10 −13 ) 10 . None of the IgAD loci outside of the major histocompatibility complex (MHC) region overlapped loci for IgA nephropathy 10 .
A previous GWAS identified the common allele IFIH1 p.Thr946Ala (OR = 0.62, control allele frequency = 0.39) as the first and, thus far, only non-HLA genome-wide significant IgAD locus 9 . The p.Thr946Ala variant is also protective for T1D 11 , SLE 12 , psoriasis 13 and vitiligo (see URLs). IFIH1 encodes MDA5, a cytosolic receptor that recognizes double-stranded RNA and initiates interferon pathway activation.
To expand understanding of IgAD risk, we studied four new IgAD cohorts and performed a GWAS meta-analysis of ~9.5 million SNPs in 1,635 cases and 4,852 controls ( Table 1) . Genotypes for untyped markers were imputed for each cohort separately (1000 Genomes Project) and genotypes for variants fully typed in the entire cohort. Up to four controls per new case were iteratively selected on the basis of ancestry eigenvectors 14 to minimize population substructure Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are associated with selective IgA deficiency 1 4 2 6 VOLUME 48 | NUMBER 11 | NOVEMBER 2016 Nature GeNetics l e t t e r s (Online Methods). Genomic inflation factor values were minimal ( Table 1) , indicating that population substructure was adequately addressed. Association analyses were conducted with logistic regression (additive model), accounting for genotype uncertainty and using ancestry eigenvectors as covariates (Online Methods).
The strongest association was with the MHC region, 2.7 kb upstream of HLA-DQA1 (P = 3.3 × 10 −92 ) ( Table 2) . Protective association between IgAD and IFIH1 p.Thr946Ala 9 was confirmed (P = 3.7 × 10 −15 ), and association with the rare loss-of-function IFIH1 p.Ile923Val variant (P = 2.6 × 10 −8 ) was subsequently identified ( Supplementary  Table 1 ). Val923 has previously been shown to be protective for T1D 11 and psoriasis 13 and abrogates interferon signaling 15 . A rare gain-offunction IFIH1 p.Arg779His variant has also been reported in an IgAD case with SLE and a type I interferon signature 16 .
Our GWAS identified four new significant (P < 5 × 10 −8 ) loci: PVT1, ATG13-AMBRA1, AHI1 and CLEC16A ( Fig. 1 and Table 2 ). The peak new IgAD variants were (i) a protective 1-bp deletion 91 kb downstream of PVT1 (P = 4.3 × 10 −11 ); (ii) a variant 289 kb upstream of ATG13 (P = 6.7 × 10 −10 ); (iii) an intronic AHI1 variant (P = 8.4 × 10 −10 ); and (iv) a protective 1-bp intronic insertion in CLEC16A (P = 1.4 × 10 −9 ) ( Table 2, Supplementary Figs. 1-6 and Supplementary  Table 2 ). Twenty-eight additional loci contained at least one variant with 5 × 10 −8 < P < 1 × 10 −5 , and half (denoted with an asterisk) were known autoimmune loci: FAS*, GATA3*, MYO9B, CD86*, BCL6, IKZF2, PTGER4*, IKZF3*, EGR2*, FCRL3*, IL2RA*, PTPN2*, IL2*-IL21*, CDH23*, MAST4, FOXP1, MIR605, LINC01098, DRMT1, LINC00299, C22orf42, FAM171A1, BACH1, ZCCHC24, NCKAP5, LOC100505887, TMEM72 and CD28* ( Supplementary Fig. 7 and Supplementary Table 3 ).
The heritability of IgAD in the Swedish cohort based on genome-wide imputed variants was 0.49 (standard error (SE) = 0.047). This estimate was reduced from 0.49 to 0.39 (SE = 0.059) when we conditioned on the five peak non-MHC variants, the peak MHC variant (rs116041786), and the peak MHC variant after conditioning on the peak MHC variant (rs116350876). When we excluded the MHC region altogether from the input, the estimated heritability dropped to 0.14 (SE = 0.054).
As one approach to compile a list of potential causative gene(s) and allele(s) in the new loci 17 , we cross-referenced the peak variants plus 160 correlated variants (r 2 ≥ 0.7) (44 variants in PVT1; 21 variants in ATG13-AMBRA1; 65 variants in AHI1; and 30 variants in CLEC16A; total n = 164) against epigenetic data, eQTLs, DNase I-hypersensitive sites (DHSs), transcription factor binding sites (ChIP-seq), consensus motifs, GWAS loci and promoter regions using RegulomeDB 18 , Encyclopedia of DNA Elements (ENCODE) 19 , Roadmap Epigenomics, Gene Expression Omnibus (GEO), Washington University EpiGenome Browser, ImmunoBase and the GWAS Catalog (see URLs). The RegulomeDB catalog lists regulatory evidence for ~60 million variants, and about 5% (~3 million) are categorized as likely to affect binding (score = 2) or likely to affect binding and linked to expression of a gene target (score = 1).
In our data set, 13.1% (21/160) of the correlated variants were likely to affect binding (RegulomeDB score <3) and were located in regions of open chromatin in an immune cell (as determined by DNase hypersensitivity) and/or in transcription factor binding sites (as determined by DNase footprints, ChIP-seq and/or binding site motifs) (Supplementary Table 4 ). Many of these variants (15/21) were also located in histone marks for active transcription (H3K4me3, H3K27ac or H3K4me1) in regulatory T (T reg ) cells, and all of the new loci, except for AHI1, encompassed at least one T reg enhancer and active transcription start site. A comparison of the overlap between eQTL data from lymphoblastoid B cells and IgAD meta P values using the Bayesian statistical framework Sherlock identified three cis-eQTLs in AHI1 and DEXI associated with IgAD (Supplementary Table 4 ).
The PVT1 locus contains no protein-coding genes, and the long noncoding RNA (lncRNA) PVT1 appears to be the most likely causative genetic element. PVT1 has been shown to be important for expression and copy number increase of MYC in tumors 20 . The peak PVT1 variant was in moderate linkage disequilibrium (LD) with four potential regulatory variants. The most interesting of these was rs7001706 (r 2 = 0.70), an intronic variant that lies in a FOXP3 transcription factor binding motif and in an H3K4me1 histone mark in T reg cells. When we conditioned the regression analyses on either the peak variant or the potential regulatory variant rs7001706, they accounted for part but not all of the effect of the locus (data not shown), indicating that PVT1 contains more than one independent signal.
AHI1 is highly expressed in hematopoietic cells and overexpressed in blood cancers 21 . AHI1 stabilizes BCR-ABL in leukemia cells by recruiting JAK2 and can regulate phosphorylation of JAK2-STAT5 (ref. 22) . JAK inhibitors are useful in treating rheumatoid arthritis, psoriasis and alopecia areata. The peak variant was in LD with eight eQTLs, all on the same haplotype. rs2064430 (r 2 = 0.85) had the strongest evidence for regulatory binding (RegulomeDB score = 1d) ( Supplementary Table 4 ). A comparison of the overlap between eQTL data from lymphoblastoid B cells and IgAD meta P value using the Bayesian statistical framework Sherlock highlighted two cis-eQTLs in AHI1 (rs2179781 and rs9647635) with strong positive log Bayes factor (LBF) scores (6.83 and 6.63, respectively) ( Supplementary Table 4 ). Of the variants highlighted in Supplementary Table 4 , rs2179781 had the smallest meta P value. rs2179781[A] was associated with reduced risk for IgAD and reduced AHI1 expression ( Supplementary Fig. 8 ).
The peak SNP upstream of ATG13 (autophagy 13) and AMBRA1 (autophagy/beclin-1 regulator 1) was correlated with two likely regulatory Table 4 ). ATG13 and AMBRA1 physically interact 23 and share the same chromatin interaction domain. Autophagy has a role in autoimmunity 24 , plasmablast differentiation 25 and immunoglobulin production in plasma cells 26 . ATG13 and AMBRA1 are the most likely risk-associated genes in this interval, but the causal variant remains to be determined. CLEC16A contains several eQTLs for DEXI 27 , and T1D-associated CLEC16A variants 28 are located in an intron that shows chromatin interaction with the DEXI promoter, as determined by 3C 27 and Hi-C 29,30 mapping. The peak variant was in LD with seven likely regulatory variants ( Supplementary Table 4 ), including rs35300161, rs34972832 and the DEXI eQTL rs17806299 (r 2 = 0.80). rs35300161 and rs34972832 are present in open chromatin in germinal center and naive B cells ( Supplementary Table 4 ) and in an enhancer in various T cell types and tissues. A comparison of the overlap between eQTL data from lymphoblastoid B cells and IgAD meta P value with Sherlock highlighted one cis-eQTL in DEXI (rs741175) with a strong positive LBF score (6.16) ( Supplementary Table 4 ).
Mice with Clec16a knockdown show reduced numbers of B cells 31 and are protected from autoimmunity 32 . Further work is required to determine whether CLEC16A or DEXI is the relevant gene in this interval.
We next applied pathway analysis to the meta-analysis results using genomic randomization (PARIS) 33 to estimate empirical significance (n = 10,000 randomizations) and an alternate pathway algorithm based on LD-independent intervals for replication (INRICH) 34 . PARIS reduces bias from gene size, pathway size, LD blocks and SNP coverage. Preliminary testing with PARIS v1.1 using imputed data has not been completed and, thus, only the GWAS chip content was selected for this experiment. Using PARIS, we grouped variants into LD features and single SNPs into linkage equilibrium (LE) features. The LD and LE features were grouped by KEGG pathways and also by our user-defined Treg signature pathway. The features in each pathway were permuted 10,000 times with a randomly selected set of features of similar size. The empirical P value is based on the number of features with P < 0.05 in a pathway, in comparison to the number of features with P < 0.05 in the permuted pathway. IgAD was associated (empirical P < 0.0001) with 7 of 221 (3%) KEGG pathways (total n genes queried = 5,701) ( Supplementary Table 5 ).
Of particular interest, one of the top pathways identified was the intestinal immune network for IgA production (empirical P < 0.0001), with 22 of 30 genes in the pathway containing variants with P < 0.05 in the IgAD meta-analysis ( Fig. 2 and Supplementary Table 6 ). These include genes encoding inflammatory and immune regulatory cytokines (IL2, IL4, IL6, IL10, IL15, APRIL and BAFF), key cell surface molecules on B and T cells (TACI, CD40, IL15R, CD28, ICOS and ICOSLG), molecules essential for the homing of lymphocytes to the gut (ITGA4, CCR9, MADCAM1, CXCL12, CCL28, LTBR and MAP3KI4) and DNA deaminase required for B cell class-switch recombination (AICDA). These data suggest that the genetic contribution to IgA deficiency includes many genes known to regulate IgA production.
Similar to rheumatoid arthritis and T1D GWAS SNPs, which are enriched for active histone marks (H3k4me3) in T reg cells 17 and lymphoid gene enhancers 35 , respectively, IgAD-associated variants were enriched for active histone marks and enhancers in T reg cells. When we applied a set of T reg signature genes (27 autosomal genes that are a Peak variants were imputed, except for those in IFIH1 and CLEC16A, which were genotyped in all but the Czech cohort. Three loci had suggestive association in our previous GWAS: PVT1 (P = 4 × 10 −6 ), DGKZ (P = 2 × 10 −6 ) and CLEC16A (P = 2 × 10 −7 ). b Autoimmune diseases reporting a genome-wide significant variant (P < 5 × 10 −8 ) in ImmunoBase and the GWAS Catalog (see URLs) with at least a modest effect (OR ≥ 1.1) in the same direction as the IgAD results and on the same haplotype as a peak IgAD variant (r 2 > 0.45) 12 . c Genetic association of IgAD with HLA class II loci is well established, particularly for HLA-DQB1*02:01 and HLA-DRB1*01:02 and for the highly protective HLA-DRB1*15:01 allele 6 . Few of the cases (2.1%) were carrying two copies of rs116041786[C] (versus 15.7% of controls). d Multiple sclerosis, rheumatoid arthritis, SLE, T1D, vitiligo, allergy and asthma also have some associations reported at this locus. e IBD is also associated with this locus. f Multiple sclerosis, celiac disease, eczema and allergy also have some associations reported at this locus. g Celiac disease and asthma also have some associations reported at this locus. l e t t e r s significantly upregulated in FOXP3 + T reg cells versus conventional FOXP3 − CD4 + T cells 36 ) as a user-defined pathway in PARIS pathway analysis, we found that the T reg signature pathway was significantly enriched for association with IgAD (empirical P < 1 × 10 −5 ) ( Supplementary Table 7 ). FOXP3 is an important transcriptional regulator of T reg differentiation 37 , and germline mutations of FOXP3 cause IPEX 38 , a disease characterized by impaired T reg function and life-threatening autoimmunity. T reg cells in B cell the germinal centers of Peyer's patches have been shown to influence the ability of sIgA to maintain microbial diversity 29 . Using GWAS summary statistics for T1D and rheumatoid arthritis, we tested for shared genetics between these two diseases and IgAD. Applying GPA 30 , we found significant shared genetics both between T1D and IgAD and between rheumatoid arthritis and IgAD. GPA uses a likelihood-ratio test to compare a model of the pairwise summary statistics with no shared genetics to a model with shared genetics. Results indicate significant shared genetics, even when variants in the MHC region were omitted (P < 1.6 × 10 −7 ).
In conclusion, we identified four new susceptibility loci for IgAD-PVT1, AHI1, AMBRA1-ATG13 and CLEC16A. Interrogation of peak IgAD variants and SNPs in LD identified 21 putative regulatory variants. Pathway analyses highlighted enrichment for association in the intestinal immune network for IgA production and in T reg signature genes. Further work is needed to validate new associations via genotyping, to identify causal variants in the new loci, to explore the regulatory role of associated variants through functional studies and to investigate autoimmune mechanisms that contribute to IgAD pathogenesis. l e t t e r s Data access. GWAS data generated in this study are accessible through Genentech, Inc., at http://research-pub.gene.com/ bronson_et_al_2016.
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ONLINE METhODS
The GWAS tested ~9.5 million variants in 1,635 patients with IgAD (clinical diagnosis defined as serum IgA ≤0.07 g/l with normal IgM and total IgG levels) 39 and 4,852 controls from seven independent case-control cohorts ( Table 1) .
Samples.
Only IgAD cases without autoimmune diseases comorbidity (for example, type 1 diabetes or celiac disease) were included in this study. Furthermore, IgAD cases were screened for celiac disease (autoantibodies to tissue transglutaminase) and excluded from the study if positive.
Genotyping. Illumina developed all of the genotyping arrays. We genotyped cases on Omni1-Quad and Omni2.5 arrays, Swedish controls (Swedish TwinGene Project) 40 Table 1 for the number of SNPs that overlapped across the arrays for each of the seven cohorts. All SNPs were mapped to build hg19 coordinates using liftOver.
Quality control after genotyping and before imputation. Before imputation, we removed variants with a genotyping rate <98%, ambiguity (A/T SNPs and C/G SNPs), evidence of deviation from Hardy-Weinberg equilibrium in controls (P < 1 × 10 −4 ), and MAF < 1 × 10 −6 . Subsequently, we removed individuals who were missing >1% of genotypes and who had heterozygosity ±6 s.d. from the mean. To estimate identity by descent (IBD) and conduct principalcomponents analysis (PCA) (EIGENSOFT v3.0; ref. 43) , we randomly selected 100,000 LD-pruned variants (LD pruning was based on r 2 > 0.2; excluding insertions and deletions, variants in regions of long-range LD 44 or in the MHC region (chr. 6: 24-36 Mb) or in a large inversion on chromosome 8 (ref. 45) , and variants with MAF <0.05) and included 878 ancestry-informative markers 46 . We estimated and plotted IBD for all pairs of samples and removed duplicate samples and cryptically related individuals (P(IBD = 0) < 0.8). For PCA, we used five outlier removal iterations and ten principal components along which to remove outliers during each outlier removal iteration. Any sample exceeding 6 s.d. along one of the principal components was considered a population outlier and was removed. We then reran PCA without the ancestry outliers. For the four new cohorts, we iteratively selected up to four controls, similarly to a previously described approach (developed by M.F.S.), to minimize population substructure differences between cases and controls 14 . Each control could only be selected once. For matching, we sequentially selected a control that passed quality control and best matched the case, considering the eigenvalue results from principal components contributing at least 1% of variance determined from principal components with significant P values (P < 0.05) in the Tracy-Wisdom test 43 . We estimated the percentage of variance explained by subtracting the eigenvector value of the first non-significant principal component from each significant principal component, summing this value and dividing each eigenvector value by the sum. Eigenvalues for each principal component were adjusted for the eigenvector scale (adjusted for the relative contribution of each eigenvector in describing the data). The lowest cumulative sum of the absolute differences (Manhattan distance for each principal component after adjustment based on relative eigenvalues) between all cases and all controls was scored as the best match.
Subsequently, we reran PCA a third time for each cohort using the final set of case-control samples. Principal components contributing at least 1% of variance determined from principal components with significant P values (P < 0.05) in the Tracy-Wisdom test 43 were used as covariates in the association analyses. Significant principal components were also plotted with cases and controls color-coded differently for visual inspection. We tested for differential genotyping rates for cases and controls but did not observe any.
Statistical analysis before imputation. We conducted χ 2 tests of association on genotypes for each cohort separately, using only variants that overlapped across the arrays used to genotype the cohort, and estimated a genomic inflation factor (λ GC ) 47 based on the median χ 2 value for non-MHC genotyped variants adjusted for ancestry (PLINK v1.07; ref. 47 ). Before meta-analysis and imputation, we plotted P values in a quantile-quantile plot (excluding the MHC region) and in a Manhattan plot in R.
